Dr Paul Huang’s team aims to understand how networks of signalling-proteins control tumour progression and drug resistance in cancer.
Dr Paul Huang uses systems biology and molecular pathology to study drug resistance in sarcomas and lung cancer. He trained at Imperial College London and Massachusetts Institute of Technology, and was awarded a Sir Henry Wellcome Fellowship in 2009 and a Cancer Research UK Career Establishment Award in 2015.
I am a higher scientific officer. My work involves Nanostring gene expression analysis to establish molecular signatures or biomarkers for targeted therapy response in sarcoma trials.
I am PhD student focusing on understanding angiosarcomas. My work involves molecular profiling of angiosarcoma patient samples to better understand mechanisms of treatment response and resistance and identify potential biomarkers.
I am currently working on utilising radiogenomics to understand heterogeneity and therapy response in soft tissue sarcoma, and whether combining imaging and molecular data can improve patient outcomes.
I'm a PhD student from Turin, Italy, and my project focuses on leiomyosarcoma, an aggressive soft tissue sarcoma subtype. My aim is to use RNA sequencing and proteomics to understand evolution of localised to metastatic disease with the goal of identifying new therapies for patients.
My research aims to identify candidate biomarkers for improving neoadjuvant therapy in high-risk soft tissue sarcomas. This convergence science project uses an explant-in-chip model developed by the Overby group, our collaborators at Imperial College London.
I'm a first year PhD student. My research is interested in developing spatial proteomic sampling techniques to better understand intratumoral heterogeneity within soft tissue sarcomas.
I am a PhD student co-supervised by Dr Sam Au at Imperial College London. My project is on developing a microfluidic chip to study how extracellular matrix components affect tumour cell behaviour during metastatic colonisation in the lung, with a focus on using hydrogels to mimic the tumour microenvironment.
I began my postdoctoral career at the ICR in 2015. Initially working for the Signal Transduction Team (Barbara Tanos) and subsequently joining the Molecular and Systems Oncology Team in 2018. My current research is focused on understanding sub-clonal interactions and tumour heterogeneity driving EGFR inhibitor resistance in lung cancer.
I am a first-year PhD student split between Imperial College London (Ishihara lab) and the Institute of Cancer Research (Huang lab). My research will be focused on the bioengineering and development of immunomodulatory agents designed to target the extracellular matrix as a novel therapeutic strategy to treat sarcoma.
I am a Higher Scientific Officer currently investigating the drug resistance mechanisms in lung cancer patients with EGFR Exon20 insertion mutations using gene editing approaches such as CRISPR-Cas9.
I’m Valeriya, a post doctoral researcher. I’m analysing matrisome and adhesome of leiomyosarcoma and using leiomyosarcoma-specific models of extracellular matrix to identify the drives of metastasis, in search for new drug targets.
I am a PhD student working to understand the mechanisms of response and resistance in alveolar soft part sarcoma to the TKI cediranib, with the aims of identifying new biomarkers and therapeutic strategies to improve patient outcome.